Association study between methylenetetrahydrofolate reductase gene polymorphisms and Graves' disease

Cell Biochemistry and Function

Volumn 28, Issue 7, 2010, Pages 585-590

  Mao, Renfang ^a   Fan, Yihui ^a   Zuo, Lulu ^a   Geng, Dongfeng ^a   Meng, Fantao ^a   Zhu, Jing ^a   Li, Qiang ^b   Qiao, Hong ^b   Jin, Yan ^a   Bai, Jing ^a   Fu, Songbin ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Second Affiliated Hospital and   (China)

^c Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

Author keywords

Autoimmunity; Genetic polymorphisms; Graves' disease; MTHFR

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); FOLIC ACID; HOMOCYSTEINE; NUCLEOTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GRAVES DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GRAVES DISEASE; HAPLOTYPES; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 78650471042     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1694     Document Type: Article

References (30)

1. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag 2010; 6: 29-40.
2. Ayadi H, Hadj Kacem H, Rebai A, Farid NR. The genetics of autoimmune thyroid disease. Trends Endocrinol Metab 2004; 15(5): 234-239.
3. Brix TH, Kyvik KO, Christensen K, Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab 2001; 86(2): 930-934.
4. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrinol Rev 2003; 24(5): 694-717.
5. Dechairo BM, Zabaneh D, Collins J, et al.Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur J Hum Genet 2005; 13(11): 1223-1230.
6. Sjakste T, Eglite J, Sochnevs A, et al.Microsatellite genotyping of chromosome 14q13.2-14q13 in the vicinity of proteasomal gene PSMA6 and association with Graves' disease in the Latvian population. Immunogenetics 2004; 56(4): 238-243.
7. Pearce SH, Merriman TR. Genetic progress towards the molecular basis of autoimmunity. Trends Mol Med 2006; 12(2): 90-98.
8. Mavragani CP, Patronas N, Dalakas M, Moutsopoulos HM. Ill-defined neurological syndromes with autoimmune background: a diagnostic challenge. J Rheumatol 2007; 34(2): 341-345.
9. Sutherland A, Davies J, Owen CJ, et al.Genomic polymorphism at the interferon-induced helicase (IFIH1) locus contributes to Graves' disease susceptibility. J Clin Endocrinol Metab 2007; 92(8): 3338-3341.
10. Afeltra A, Vadacca M, Conti L, et al.Thrombosis in systemic lupus erythematosus: congenital and acquired risk factors. Arthritis Rheum 2005; 53(3): 452-459.
11. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348(9035): 1120-1124.
12. Foffa I, Festa PL, Ait-Ali L, Mazzone A, Bevilacqua S, Andreassi MG. Ascending aortic aneurysm in a patient with bicuspid aortic valve, positive history of systemic autoimmune diseases and common genetic factors: a case report. Cardiovasc Ultrasound 2009; 7: 30-34.
13. Frosst P, Blom HJ, Milos R, et al.A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. NJT Genet 1995; 10(1): 111-113.
14. van der Put NM, Gabreels F, Stevens EM, et al.Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 1998; 62(5): 1044-1051.
15. Rady PL, Szucs S, Grady J, et al.Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR) in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 2002; 107(2): 162-168.
16. Melo SS, Persuhn DC, Meirelles MS, Jordao AA, Vannucchi H. Polymorphisms in the methylene-tetrahydrofolate gene: effect of folic acid on homocysteine levels. Mol Nutr Food Res 2006; 50(8): 769-774.
17. Mao R, Fan Y, Chen F, Sun D, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms in 13 Chinese ethnic populations. Cell Biochem Funct 2008; 26(3): 352-358.
18. Mao R, Fan Y, Chen F, Fu S. Genetic polymorphism of MTHFR G1793A in Chinese populations. Eur J Epidemiol 2008; 23(5): 363-368.
19. Papoutsakis C, Yiannakouris N, Manios Y, et al.Plasma homocysteine concentrations in Greek children are influenced by an interaction between the methylenetetrahydrofolate reductase C677T genotype and folate status. J Nutr 2005; 135(3): 383-388.
20. Papoutsakis C, Yiannakouris N, Manios Y, et al.The effect of MTHFR(C677T) genotype on plasma homocysteine concentrations in healthy children is influenced by gender. Eur J Clin Nutr 2006; 60(2): 155-162.
21. Rook JL, Nugent DJ, Young G. Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutations. J Pediatr Hematol Oncol 2005; 27(11): 590-593.
22. Slattery ML, Potter JD, Samowitz W, Schaffer D, Leppert M. Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 1999; 8(6): 513-518.
23. Le Marchand L, Donlon T, Hankin JH, Kolonel LN, Wilkens LR, Seifried A. B-vitamin intake, metabolic genes, and colorectal cancer risk (United States). Cancer Causes Control 2002; 13(3): 239-248.
24. Matsuo K, Hamajima N, Suzuki R, et al.Methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms and reduced risk of malignant lymphoma. Am J Hematol 2004; 77(4): 351-357.
25. Jiang Q, Chen K, Ma X, et al.Diets, polymorphisms of methylenetetrahydrofolate reductase, and the susceptibility of colon cancer and rectal cancer. Cancer Detect Prev 2005; 29(2): 146-154.
26. Richardson B. DNA methylation and autoimmune disease. Clin Immunol 2003; 109(1): 72-79.
27. Chen Z, Karaplis AC, Ackerman SL, et al.Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. Hum Mol Genet 2001; 10(5): 433-443.
28. Stern LL, Mason JB, Selhub J, Choi SW. Genomic DNA hypomethylation, a characteristic of most cancers, is present in peripheral leukocytes of individuals who are homozygous for the C677T polymorphism in the methylenetetrahydrofolate reductase gene. Cancer Epidemiol Biomarkers Prev 2000; 9(8): 849-853.
29. Li K, Liu S, Yao S, Wang B, Dai D, Yao L. Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer's disease risk. Dement Geriatr Cogn Disord 2009; 27(3): 286-291.
30. Li K, Sun Y, Chen L. The common C677T polymorphism in the methylenetetrahydrofolate reductase gene is associated with neural tube defects and preeclampsia. Zhonghua Fu Chan Ke Za Zhi 2000; 35(4): 205-207.